Devonian Announces Delay in Financial Results Release Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for inflammatory diseases, has announced a delay in filing its…
LucyRx Unveils Bold Brand Identity, Celebrates Key Milestones to Simplify PBM and Enhance Patient Care LucyRx, a next-generation pharmacy benefit manager (PBM), is shaking up the landscape of prescription care with its innovative approach, compassionate values, and impressive growth. With…
Omeros Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results Omeros Corporation has announced its recent developments, clinical updates, and financial results for the fourth quarter and full year ended December 31, 2024. Financial Highlights: Clinical Developments: Other Developments: CEO’s…
BeiGene’s TEVIMBRA® Gets CHMP Nod for First-Line Lung Cancer Treatment BeiGene, Ltd., a global oncology company soon to be rebranded as BeOne Medicines Ltd., has announced a significant milestone in its efforts to expand cancer treatment options. The Committee for…
WuXi Biologics Achieves ISO 22301 Certification and Expands ISO/IEC 27001 Compliance WuXi Biologics (“WuXi Bio”) (2269.HK), a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a significant milestone in its ongoing commitment to operational resilience and information…
Ono & Reborna Partner for CNS RNA-Targeting Drug Discovery Ono Pharmaceutical Co., Ltd. (Headquartered in Osaka, Japan; President and COO: Toichi Takino; hereafter referred to as “Ono”) has announced a strategic collaboration agreement with Reborna Biosciences, Inc. (Headquartered in Kanagawa,…
Halozyme Announces Positive CHMP Opinion for Bristol Myers Squibb’s Subcutaneous Opdivo® with ENHANZE Halozyme Therapeutics, Inc. (NASDAQ: HALO) recently announced a significant milestone in oncology treatment development, as Bristol Myers Squibb has received a positive opinion from the Committee for…
ACC 2025 Sensydia CPS™ Accurately Assesses Mean Pulmonary Artery Pressure Non-Invasively Sensydia, a clinical-stage company specializing in non-invasive cardiac assessment technologies, has announced promising results from a recent clinical study evaluating its AI-powered Cardiac Performance System (CPS™). These findings were…
FDA Clears Siemens Antithrombin Test as Companion Diagnostic for Qfitlia Siemens Healthineers has announced that its Innovance Antithrombin assay has received FDA clearance for an additional claim, allowing it to be used as a companion diagnostic test for individuals receiving…
BMS Gets CHMP Nod for Opdivo-Based Perioperative Regimen in Resectable NSCLC Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval…
Xeris Announces Board Changes Xeris Biopharma Holdings, Inc., a growth-oriented biopharmaceutical company dedicated to enhancing patient care through the development and commercialization of innovative therapies, has announced significant changes to its board of directors. These changes come as part of…
Equillium Announces Q4 & Full-Year 2024 Results, Corporate & Clinical Updates Equillium, Inc., a clinical-stage biotechnology company specializing in immunobiology, has reported its financial results for the fourth quarter and full year 2024, alongside recent corporate and clinical developments. The…